| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/08/2010 | WO2010039798A2 Amorphous compositions of sunitinib base and l-malic acid |
| 04/08/2010 | WO2010039762A2 Pharmaceutical compositions comprising boronic acid compounds |
| 04/08/2010 | WO2010039740A1 PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR |
| 04/08/2010 | WO2010039668A2 Inhibitors of cyclin kinase inhibitor p21 |
| 04/08/2010 | WO2010039518A2 Tricyclic carbamate jak inhibitors |
| 04/08/2010 | WO2010039248A1 Methods for the treatment of cancer |
| 04/08/2010 | WO2010039187A2 Fused diimidazodiazepine compounds and methods of use and manufacture thereof |
| 04/08/2010 | WO2010039039A1 Oral formulations of gemcitabine derivatives |
| 04/08/2010 | WO2010038465A1 8-substituted isoquinoline derivative and use thereof |
| 04/08/2010 | WO2010038428A1 Alternative agent to taxane anti-cancer agent |
| 04/08/2010 | WO2010038165A1 Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions |
| 04/08/2010 | WO2010038060A1 Heterocyclic jak kinase inhibitors |
| 04/08/2010 | WO2010038043A1 Pyrimide derivatives and their pharmaceutical use |
| 04/08/2010 | WO2010038041A1 Antimicrobial compounds |
| 04/08/2010 | WO2010037886A1 Chroman derivatives and uses thereof as inhibitors of the activity of decoupling proteins |
| 04/08/2010 | WO2010037856A2 DYNACTIN-1/p150glued AS A TARGET FOR TUMOR DIAGNOSIS AND THERAPY AND A METHOD FOR IDENTIFYING TARGETABLE DISEASE-RELATED PROTEINS |
| 04/08/2010 | WO2010037765A2 4-morpholino-pyrido[3,2-d]pyrimidines |
| 04/08/2010 | WO2010037715A1 Smoothened antagonism for the treatment of hedgehog pathway-related disorders |
| 04/08/2010 | WO2010037539A1 Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| 04/08/2010 | WO2010037536A1 N-protected guanidine-substituted furans, thiophenes, and pyrrols as cysteine protease inhibitors |
| 04/08/2010 | WO2010037514A2 Novel immunotherapy against several tumors including neuronal and brain tumors |
| 04/08/2010 | WO2010037513A1 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers |
| 04/08/2010 | WO2010037408A1 Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| 04/08/2010 | WO2010037395A2 Mhc multimers in cancer vaccines and immune monitoring |
| 04/08/2010 | WO2010037352A1 Pharmaceutical composition utilising combinations of variants of the gonadotropin-liberating hormone (gnrh) as immunogen |
| 04/08/2010 | WO2010037351A1 Peptide antagonist of interleukin-15 activity |
| 04/08/2010 | WO2010037339A1 Aminoquinazoline derivatives and their salts with antineoplastic activity |
| 04/08/2010 | WO2010037284A1 Polypeptides for treating or preventing cancers, the derivative products and uses thereof |
| 04/08/2010 | WO2010037252A1 Sulfated derivative of gastrodia elata polysaccharide, preparation method and use thereof |
| 04/08/2010 | WO2010037249A1 5,8-disubstituted-1,6-naphthyridine-7-carbonyl amide compounds, their preparation methods, compositions and use |
| 04/08/2010 | WO2010037179A1 Anionic conjugates of glycosylated bacterial metabolite |
| 04/08/2010 | WO2010011289A3 Parenteral and oral formulations of benzimidazoles |
| 04/08/2010 | WO2010007318A3 Imidazo [1, 2-a] pyrimidine derivatives method for the production thereof application thereof as medicaments pharmaceutical compositions and use thereof as met inhibitors |
| 04/08/2010 | WO2010007248A3 Novel tricyclic derivatives, process for the preparation thereof and pharmaceutical compositions containing same |
| 04/08/2010 | WO2010006234A3 Anticancer oral formulation |
| 04/08/2010 | WO2010006172A3 2-methylene-20(21)-dehydro-19-nor-vitamin d analogs |
| 04/08/2010 | WO2010005534A3 Proteasome inhibitors for selectively inducing apoptosis in cancer cells |
| 04/08/2010 | WO2009155556A3 Crkl targeting peptides |
| 04/08/2010 | WO2009135019A3 Methods and compositions for prostate cancer immunotherapy |
| 04/08/2010 | WO2009115084A3 Pyrrolopyrimidine derivatives, and use thereof |
| 04/08/2010 | US20100088775 Methods of modulating epithelial-mesenchymal transition and mesenchymal-epithelial transition in cells and agents useful for the same |
| 04/08/2010 | US20100087909 Catheter balloon systems and methods |
| 04/08/2010 | US20100087544 N, n -dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same |
| 04/08/2010 | US20100087527 Curcumin Derivatives |
| 04/08/2010 | US20100087526 Inhibitors of polyisoprenylated methylated protein methyl esterase |
| 04/08/2010 | US20100087521 Biologically active complex |
| 04/08/2010 | US20100087515 Ikk-beta serine-threonine protein kinase inhibitors |
| 04/08/2010 | US20100087513 Microrna molecules |
| 04/08/2010 | US20100087512 Microrna molecules |
| 04/08/2010 | US20100087510 Novel Adaptor protein that binds to mammalian toll-like receptor 3 and gene thereof |
| 04/08/2010 | US20100087505 Compounds Having Aryl-Sulphonamidic Structure Useful As Metalloproteases Inhibitors |
| 04/08/2010 | US20100087499 Pharmaceutical compositions and methods of using temozolomide and multi-targeted kinase inhibitors |
| 04/08/2010 | US20100087482 Method for Treating Gefitinib Resistant Cancer |
| 04/08/2010 | US20100087477 Selective glycosidase inhibitors |
| 04/08/2010 | US20100087473 Freeze-dried injectable pharmaceutical combination of semisynthetic vinca alkaloids and carbohydrate stable at room temperature |
| 04/08/2010 | US20100087467 Compositions Useful As Inhibitors of Protein Kinases |
| 04/08/2010 | US20100087464 Protein kinase inhibitors and methods for using thereof |
| 04/08/2010 | US20100087463 Pharmaceutical compositions comprising nilotinib or its salt |
| 04/08/2010 | US20100087459 Forms of lapatinib compounds and processes for the preparation thereof |
| 04/08/2010 | US20100087458 Method of treating melanoma |
| 04/08/2010 | US20100087456 PYRIDOPYRIMIDINONE INHIBITORS OF PI3K-ALPHA and mTOR |
| 04/08/2010 | US20100087455 Substituted xanthine compounds |
| 04/08/2010 | US20100087449 Heteroarylamide pyrimidone compounds |
| 04/08/2010 | US20100087443 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators |
| 04/08/2010 | US20100087442 Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient |
| 04/08/2010 | US20100087440 Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use |
| 04/08/2010 | US20100087431 Triazolyl aminopyrimidine compounds |
| 04/08/2010 | US20100087399 Use of 9-oxoacridine-10-acetic acid, salts and esters thereof in combination therapy of ovarian cancer |
| 04/08/2010 | US20100087398 Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions |
| 04/08/2010 | US20100087387 Five- and six-membered conformationally locked 2',4'-carbocyclic ribo-thymidines for the treatment of infections and cancer |
| 04/08/2010 | US20100087384 Jasmonate based assays for identifying compounds that selectively inhibit mitochondrial bound hexokinases |
| 04/08/2010 | US20100087378 Compositions and Methods for Treating Diseases Associate with Angiogenesis and Inflammation |
| 04/08/2010 | US20100087377 Peptide facilitating the entry of a linked molecule into a mammalian cancer cell; copper binding protein; inhibit the development of premalignant lesions in mammalian tissue |
| 04/08/2010 | US20100087376 Cancer related isoforms of components of transcription factor complexes as biomarkers and drug targets |
| 04/08/2010 | US20100087370 Modulation of nitric oxide signaling to normalize tumor vasculature |
| 04/08/2010 | US20100087363 Glycan modified soluble receptors and binding protein and their use |
| 04/08/2010 | US20100087358 NOTCH mutations leading to increased receptor signaling |
| 04/08/2010 | US20100087001 Anti-angiogenic cellular agent for cancer therapy |
| 04/08/2010 | US20100086985 Nucleic acid and corresponding protein entitled 205p1b5 useful in treatment and detection of cancer |
| 04/08/2010 | US20100086570 Cancer immunotherapy predictive parameters |
| 04/08/2010 | US20100086565 Vectors for expression of hml-2 polypeptides |
| 04/08/2010 | US20100086560 Chemokines as adjuvants of immune response |
| 04/08/2010 | US20100086559 Polypeptide formulation |
| 04/08/2010 | US20100086557 Pharmaceutical composition for tumor treatment |
| 04/08/2010 | US20100086540 Co-crystal of antibody 11f8fab fragment and egfr extracellular domain and uses thereof |
| 04/08/2010 | US20100086537 Polynucleotides and polypeptide sequences involved in cancer |
| 04/08/2010 | US20100086530 Cancer-tumor necrosis by artery nutrient-oxygen blocking |
| 04/08/2010 | US20100086526 Nucleic acid constructs and methods for specific silencing of h19 |
| 04/08/2010 | US20100086518 Treatment of melanoma |
| 04/08/2010 | US20100086515 Human il-4 muteins in cancer therapy |
| 04/08/2010 | US20100086486 Genetically modified human natural killer cell lines |
| 04/08/2010 | DE102007021043B4 Alpha-Form von Imatinib Mesylat und Verfahren zu seiner Herstellung Alpha-form of imatinib mesylate and a process for its preparation |
| 04/08/2010 | CA2742550A1 4-morpholino-pyrido[3,2-d]pyrimidines |
| 04/08/2010 | CA2739387A1 Novel immunotherapy against several tumors including neuronal and brain tumors |
| 04/08/2010 | CA2739384A1 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers |
| 04/08/2010 | CA2739083A1 Methods for suppressing toll-like receptor activity |
| 04/08/2010 | CA2738993A1 Pharmaceutical composition utilising combinations of variants of the gonadotropin-releasing hormone (gnrh) as immunogen |
| 04/08/2010 | CA2738974A1 Antimicrobial compounds |
| 04/08/2010 | CA2738925A1 Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors |
| 04/08/2010 | CA2738868A1 Smoothened antagonism for the treatment of hedgehog pathway-related disorders |